In last trading session, Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) saw 1.55 million shares changing hands with its beta currently measuring 0.35. Company’s recent per share price level of $32.37 trading at $1.1 or 3.52% at ring of the bell on the day assigns it a market valuation of $3.01B. That closing price of CRNX’s stock is at a discount of -93.17% from its 52-week high price of $62.53 and is indicating a premium of 25.55% from its 52-week low price of $24.10. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.96 million shares which gives us an average trading volume of 996.40K if we extend that period to 3-months.
For Crinetics Pharmaceuticals Inc (CRNX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.18. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.95 in the current quarter.
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) trade information
Upright in the green during last session for gaining 3.52%, in the last five days CRNX remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $32.37 price level, adding 1.58% to its value on the day. Crinetics Pharmaceuticals Inc’s shares saw a change of -36.69% in year-to-date performance and have moved 9.14% in past 5-day. Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) showed a performance of -9.93% in past 30-days. Number of shares sold short was 8.54 million shares which calculate 7.96 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 75.5 to the stock, which implies a rise of 57.13% to its current value. Analysts have been projecting 60 as a low price target for the stock while placing it at a high target of 91. It follows that stock’s current price would drop -85.36% in reaching the projected high whereas dropping to the targeted low would mean a loss of -85.36% for stock’s current value.
Crinetics Pharmaceuticals Inc (CRNX) estimates and forecasts
This year revenue growth is estimated to rise 483.82% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 100k for the same. And 11 analysts are in estimates of company making revenue of 347.91k in the next quarter. Company posted 640k and 399k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -12.11% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -10.98% while estimates for its earnings growth in next 5 years are of 3.49%.
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)’s Major holders
Insiders are in possession of 2.14% of company’s total shares while institution are holding 110.91 percent of that, with stock having share float percentage of 113.34%. Investors also watch the number of corporate investors in a company very closely, which is 110.91% institutions for Crinetics Pharmaceuticals Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CRNX for having 6.23 million shares of worth $279.06 million. And as of 2024-06-30, it was holding 7.8857 of the company’s outstanding shares.
The second largest institutional holder is DRIEHAUS CAPITAL MANAGEMENT LLC, which was holding about 6.11 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.7361 of outstanding shares, having a total worth of $273.76 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.81 shares of worth $91.04 million or 3.02% of the total outstanding shares. The later fund manager was in possession of 2.4 shares on Mar 31, 2025 , making its stake of worth around $77.83 million in the company or a holder of 2.58% of company’s stock.
